Although, in general, higher levels of TMB in cancer can lead to more infiltration of CD8+ T cells and thus contribute to a better prognosis by exerting an antitumor effect, KIRC has been shown to be cancer that challenged conventional thinking about cancer immunology based on this evidence that KIRC has a modest mutation burden but is responsive to immunotherapy and higher CD8+ T-cell infiltration is usually associated with a poorer prognosis [36, 37]. Here, CD8A is linked to cancer.